AbClon Inc. Overview
AbClon is a Seoul-based, clinical-stage oncology biotech. It was founded in 2010 by Lee Jong-seo and Swedish collaborators from the Human Protein Atlas programme. Its edge is epitope discovery: the NEST platform finds antibodies that bind new sites on validated cancer targets.
That approach has produced two clinical assets. The first is AC101 (HLX22), a HER2 antibody licensed worldwide to Shanghai Henlius. It is in a global Phase 3 trial (about 550 patients) for first-line HER2-positive gastric cancer, with launch targeted for 2028. The second is nespecel (AT101), a CD19 CAR-T built on a proprietary humanised binder (h1218) rather than the FMC63 binder used by all approved CD19 CAR-Ts. Its Korean Phase 2 completed enrolment in July 2026, and a Korean approval filing is planned by end-2026. Chong Kun Dang holds Korean marketing priority rights.
Behind these sit a switchable CAR-T platform (zCAR-T), 4-1BB bispecifics (AffiMab), and a new in vivo CAR-T effort with Strike Pharma and GC Biopharma. Revenue is small: KRW 4.7bn in FY2025. Operating losses run at about KRW 15–18bn a year, funded by repeated equity-linked raises.
Company self-description (paraphrased from IR and disclosure materials)
AbClon describes itself as an innovative antibody-drug venture focused on hard-to-treat cancers. It operates three core discovery platforms, NEST, AffiMab and CAR-T, and maintains a repeatable process for generating new antibody drug candidates.
Its business model, as described to data vendors and in its disclosures, combines several elements:
-
Collaborative research with Swedish partners, including Atlas Therapeutics, Affibody and Alligator Bioscience.
-
Licensing of candidates at the preclinical or early clinical stage to monetise discovery output.
-
A newer ambition to commercialise its own CAR-T in Korea through Chong Kun Dang (Valueline company summary, 2Q26 update; AbClon IR deck, Mar-2026).
The March 2026 IR deck frames the company as a global bio-innovator. It says AbClon develops next-generation CAR-T and bispecific immunotherapies on top of a differentiated antibody platform.
Independent characterisation
What the company does. AbClon is an R&D-stage platform biotech with two de-risked assets and a long preclinical tail.
-
The antibody franchise has already been out-licensed. AC101/HLX22 is Henlius' asset to develop and sell. AbClon's economic interest is limited to:
-
Remaining milestones. All USD 30M of global-deal milestones are sales-based.
-
Tiered royalties of 3–5% on product sales.
-
Alligator Bioscience is entitled to 35% of AbClon's Henlius-derived income. AbClon therefore keeps roughly 65% of that income.
-
(NewDaily, 2 Sep 2026; Alligator Bioscience press release, 23 Apr 2026)
-
-
The cell-therapy franchise is owned and operated by AbClon:
-
It runs clinical development of nespecel itself.
-
It owns a small GMP facility.
-
It has licensed Turkish rights to TCT Health Technology and given Chong Kun Dang a domestic sales-priority right.
-
Revenue model today. Reported revenue is not drug revenue. It comes mainly from product sales of reagents and analytical standards, many won through public tenders from Korean agencies such as the Korea Disease Control and Prevention Agency (KDCA) and the National Institute of Food and Drug Safety Evaluation (NIFDS). Smaller amounts come from service income and occasional licence milestones.
-
2Q26 revenue mix: 85% goods, 15% services (Butler.works, based on the 2Q26 filing).
-
Contract examples:
-
KDCA reagent contract: KRW 309M (27 Aug 2025).
-
NIFDS pesticide-residue reference-standard contract: KRW 778M (9 Mar 2026).
-
NIFDS supply contract: KRW 824M (4 Aug 2026).
-
(DART filings as reported by DigitalToday, Dealsite and AlphaDistill)
-
-
The FY2024 revenue miss (KRW 2.34bn) happened because auditors required goods sales to be booked net rather than gross (Dealsite, 15 May 2025). This shows how thin and accounting-sensitive the base is.
Value chain position. AbClon sits in upstream discovery and early-to-mid clinical development. For nespecel it has moved into late-stage development and small-scale manufacturing. It has no sales force. Commercialisation is delegated to partners: Henlius globally for AC101, Chong Kun Dang in Korea and TCT in Türkiye for nespecel.
Customer types.
-
Licensees and pharma partners: Henlius, TCT, Chong Kun Dang.
-
Government laboratories buying reagents.
-
Prospectively, hospitals and payers for CAR-T in Korea, via its partner.
End-markets.
-
HER2-positive gastric and gastro-oesophageal junction cancer (first line).
-
HER2-positive and HER2-low breast cancer, through Henlius.
-
Relapsed/refractory large B-cell lymphoma (third line, possibly second line later).
-
Preclinical solid tumours: prostate, colorectal, ovarian and other HER2-expressing tumours.
-
Autoimmune disease (preclinical).
-
Neurological disease (BBB-shuttle discovery).
Revenue model mix (FY2025, qualitative).
-
Product (reagent/standard) sales: majority.
-
Services: minority.
-
Licensing: episodic.
-
Subscription: none.
-
No royalty income has been booked yet, because no AbClon-originated drug is marketed.
Strategy
Stated strategy (paraphrased from IR, Mar-2026, and management statements)
Theme 1 — Differentiated epitopes: Use the NEST platform to find binding sites on validated targets that deliver new mechanisms, such as dual HER2 blockade with trastuzumab or a CD19 epitope that FMC63 cannot reach.
Theme 2 — From licensor to commercial-stage company: Secure Korean approval of nespecel, giving AbClon a first owned commercial product. Use partner channels: Chong Kun Dang in Korea and TCT for Türkiye, Europe and the Middle East.
Theme 3 — Early licensing as a funding model: Out-license preclinical and early clinical assets such as AM109, AT501 and in vivo CAR-T to generate cash, as already done with AC101.
Theme 4 — Next-generation cell therapy: In vivo CAR-T is positioned as the next growth engine: same-day "off-the-shelf" dosing without leukapheresis or lymphodepletion (BioSpectator, 30-Jan-2026). zCAR-T is positioned for solid tumours.
Management framing: The company called 2026 the year it would shed administrative-issue status and leap to a global biotech (shareholder letter reported by Kukinews, 30-Jan-2026).
Initiatives announced in the last 24 months
| Date | Initiative | Detail | Source |
|---|---|---|---|
| Feb-2025 | TCT Türkiye licence | Covers the CAR sequence plus manufacturing, analytics and CMC transfer. TCT bears all Turkish development and commercial costs; milestones are tied to IND; royalties on net sales. | BioSpectator |
| May-2025 | Chong Kun Dang alliance | Equity investment plus Korean sales priority for nespecel. A joint development committee covers HER2 CAR-T (AT501) and PSMA, CD30 and 4-1BB programmes. | CEO Score Daily |
| Jul/Sep-2025 | MFDS expedited pathway | Applied 23-Jul-2025; designated 24-Sep-2025 | Korea Economic Daily |
| Oct-2025 | Capital structure reset | KRW 36bn of equity-classified perpetual CB and CPS to cure the pre-tax-loss test | Dealsite |
| Jan-2026 | In vivo CAR-T platform launch | Built through Swedish biotech and domestic partnerships | BioSpectator |
| Feb-2026 | Strike Pharma Eurostars project | StAb19 (in vivo CD19), up to EUR 1M | CB Insights / BioSpectator |
| Apr-2026 | AACR 2026 out-licensing push | zCAR-T and AM109 data | Korea Economic Daily |
| Jun-2026 | GC Biopharma in vivo CAR-T partnership | Joint platform, then preclinical, clinical and global partnering | BioSpectator |
| Jul-2026 | TCT co-development cooperation (expanded) | Headline reported; terms not disclosed | Asia Economy headline list |
| 2026 (planned) | Investigator-initiated trial in post-CAR-T relapse; second-line investigator trial; Türkiye IND; AT501 IND | Per IR timeline | AbClon IR |
Medium-term targets and guidance
| Item | Target | Source |
|---|---|---|
| Nespecel MFDS approval filing | By end-2026 | Dealsite, Jul-2026 |
| Nespecel Korean launch | 2,027 | Dealsite, Jul-2026 |
| HLX22 Phase 3 topline | 1H27 (AbClon) vs 2H27 (Henlius, Aug-2026) | NewDaily |
| HLX22 commercial launch | 2028 (both companies) | NewDaily |
| AT501 IND | 2,026 | IR |
| HLX49 IND | 2026 (Henlius) | Asia Economy |
Financial guidance: no revenue or profit guidance has been issued.
ESG and sustainability commitments: none disclosed.
Products & Services
AbClon has no marketed drugs. The catalogue below covers every disclosed pipeline programme, grouped by platform (AbClon IR deck, Mar-2026, pages 5–6, unless noted).
NEST platform (Novel Epitope Screening Technology) — monoclonal antibodies
AC101 (Henlius code HLX22) — anti-HER2 monoclonal antibody
Mechanism: - Binds subdomain IV of HER2 at a different site from trastuzumab, so the two antibodies can bind HER2 at the same time.
-
Together they promote HER2 internalisation and degradation of HER2 dimers.
-
Published work (J Transl Med, Jul-2024; Med, Jul-2024) reports inhibition of both HER2/HER2 homodimers and HER2/EGFR heterodimers, with HER2 internalisation increased by roughly 40–80% (AbClon IR).
Licensee: - Shanghai Henlius Biotech, a Fosun Pharma company. It holds worldwide rights: China since 2016, global since 2018.
Clinical programmes (Henlius-run): 1. First-line HER2+ gastric/GEJ cancer, Phase 3 (PHAROS001 / HLX22-GC-301; NCT06532006).
-
Regimen: AC101 at 15 mg/kg plus trastuzumab plus chemotherapy (± pembrolizumab), versus placebo plus trastuzumab plus chemotherapy (± pembrolizumab).
-
Design: about 550 patients; dual primary endpoints of PFS and OS.
-
Enrolment: 428 patients (77.8%) by Aug-2026. Regional split: China 58.4%, Japan 12.1%, Europe 11.9%, US 4.7%, other 12.9%.
-
Topline: Henlius now guides to 2H27; AbClon's 13-Aug-2026 shareholder letter still said 1H27.
-
Launch target: 2028.
-
Sources: NewDaily (2 Sep 2026); BioSpectator.
-
HER2-low, HR+ breast cancer, Phase 2 (China). AC101 plus trastuzumab deruxtecan (Enhertu). First patient Apr-2025; enrolment completed Feb-2026 (AbClon IR).
-
First-line HER2+ breast cancer, Phase 2/3. AC101 plus HLX87 (Henlius' HER2 ADC), with the aim of a chemotherapy-free regimen. First patient Feb-2026 (AbClon IR).
-
Neoadjuvant HER2+ breast cancer. AC101 plus HLX87, investigator-initiated trial (AbClon IR).
-
HER2-expressing solid tumours, Phase 2 (China). AC101 plus trastuzumab plus chemotherapy, or AC101 plus Enhertu. NMPA approval reported Dec-2024 (BioSpectator).
-
Other indications listed in the IR deck: HER2 pancreatic cancer, and HER2 gastric cancer with serplulimab (anti-PD-1). AbClon states that AC101 is in clinical trials across six indications (Asia Economy, Apr-2026).
Regulatory status: - US FDA Orphan Drug Designation for gastric cancer (Mar-2025).
-
European Commission Orphan Drug Designation (May-2025).
-
Source: BioSpectator.
Key efficacy data (HLX22 Phase 2, first-line HER2+ gastric cancer)
-
Median PFS not reached at 39 months of follow-up; PFS hazard ratio 0.20.
-
OS hazard ratio 0.60 (95% CI 0.28–1.21; not yet statistically mature).
-
Two-year PFS 54.8% versus 17.5% for control.
-
Control median PFS 8.2–8.3 months.
-
Sources: NewDaily (Sep-2026); AbClon IR; ESMO GI 2024 via BioSpectator.
Pricing: - Not applicable to AbClon (licensed). Royalties of 3–5% are tiered by sales band.
HLX49 — HER2 biparatopic ADC (Henlius-originated derivative)
-
Combines the AC101 binding site (domain IV) with the trastuzumab binding site (domain II) in a single ADC.
-
Preclinical data at AACR 2026:
-
Higher internalisation and anti-tumour activity than Enhertu in BT-474 and NCI-N87 models.
-
Tumour reduction after a single 6 mg/kg dose.
-
Activity in HER2-ultralow (IHC <1+) models.
-
No serious toxicity in primates up to 60 mg/kg repeat dosing.
-
-
Henlius targets an IND in 2026.
-
Alligator holds participation rights in HLX49 and future derivatives, which implies AbClon's agreement covers derivatives.
-
Sources: Asia Economy (22 Apr 2026); Alligator Bioscience (23 Apr 2026).
AC104 — anti-VEGFR2 antibody
-
European patent granted May-2020.
-
Current development status not disclosed (Dealsite/PaxNet, 2020).
CAR-T platform — autologous (ex vivo)
AT101 / nespecel (nespe-cel, 네스페셀) — CD19 CAR-T
Construct and mechanism: - Humanised anti-CD19 scFv "h1218", discovered with NEST, plus a 4-1BB co-stimulatory domain and a CD8 hinge (IR schematic).
-
h1218 binds a membrane-proximal epitope (exon 2) of CD19. FMC63, used in Kymriah, Yescarta, Breyanzi, Tecartus and (as a modified version) Autolus' product, binds exons 3–4 further from the membrane.
-
The binder has fast on/off kinetics, which the company calls "Flying Kiss". It argues this limits T-cell exhaustion and enables serial killing (Molecular Cancer, Dec-2023).
-
Claimed benefits:
-
Activity against CD19 variants and masked CD19 that escape FMC63-based products.
-
Lower immunogenicity because the binder is humanised.
-
Freedom to operate outside FMC63 intellectual property.
-
Clinical programmes: 1. Third-line r/r DLBCL — Phase 1/2 (NCT05338931), registrational intent for Korea.
-
Phase 1 (n=12, four hospitals): MTD not reached; CR 66.7%, ORR 91.7%. Mid- and high-dose cohorts are reported variously as CR 83% / ORR 100% (initial CRO readout) or 6/6 CR (later update).
-
Phase 1 follow-up: 16.4-month OS rate 82.5% and PFS rate 66.7% (ASCO 2024).
-
Phase 2 (seven hospitals; 5×10^6 cells/kg; fludarabine/cyclophosphamide conditioning):
-
EHA 2025 interim: 45 enrolled, 44 manufactured (97.8%), 35 dosed, 32 evaluable.
-
ORR 94%; CR 63%, later updated to 68%.
-
Enrolment completed 2-Jul-2026. Final data and an MFDS filing are planned within 2026, with launch targeted for 2027.
-
-
Sources: BioSpectator; Finance Scope; Dealsite (Jul-2026).
-
r/r DLBCL after prior CAR-T failure. Asan Medical Center investigator-initiated trial; IND planned for 2026 (Dailypharm, Dec-2025; AbClon IR).
-
Türkiye, second/third-line DLBCL. Partnered with TCT; IND planned for 2026 (AbClon IR).
-
Second-line DLBCL expansion. Investigator-initiated trial; IND planned for 2026 (AbClon IR).
Regulatory designations (MFDS): - Orphan drug (development stage).
-
Advanced biopharmaceutical expedited-review designation (Sep-2025).
-
GIFT (Global Innovative products on Fast Track).
Patents: - Korea, US, Japan, China, Canada and Australia granted; exclusivity runs to at least 2038.
- Europe (EP3722313) under examination.
Pricing: - Not yet set. The CEO has spoken of up to about KRW 700bn in annual sales potential as a long-run aspiration (Korea Economic Daily, Dec-2025).
AT201 — CD19 dual/tandem CAR-T (blood cancer). Discovery/preclinical.
AT301 — PSMA CAR-T (prostate cancer). Discovery/preclinical.
AT601 — CD30 CAR-T with BTLA knockout (CD30+ lymphoma). Preclinical. Co-developed with UPenn; US patent granted Jul-2026 (THE VC news feed; Asia Economy).
Allogeneic CAR-T programme. Enabled by the 2022 G+FLAS CRISPR licence. Current status not disclosed.
zCAR-T switchable CAR-T platform
Concept: - A universal CAR recognises cotinine, a nicotine metabolite with an LD50 of 2–4 g/kg.
-
A separate "switch" molecule (cotinine conjugated to an affibody about 1/25 the size of an antibody) links the CAR-T cell to a tumour antigen.
-
Changing the switch dose and schedule turns T-cell activity up or down, which addresses cytokine release syndrome. Swapping the affibody re-targets the same cells to a different antigen.
Programmes: AT501 (HER2; gastric, breast and ovarian solid tumours): Preclinical. Switch-dependent tumour clearance shown in vivo. An IND is targeted in 2026 (IR, Mar-2026). US platform patent granted Sep-2025 (Kormedi).
AT502 (PD-L1; solid tumours): Preclinical.
AffiMab bispecific platform (antibody plus affibody)
AM105 (EGFR × 4-1BB, CD137) — metastatic colorectal cancer: - Activates T cells only when bound to EGFR on tumour cells, so activity does not depend on downstream EGFR mutations.
-
Targets cetuximab-resistant patients and "cold" tumours.
-
Preclinical.
-
AM109 (PSMA × 4-1BB) — metastatic castration-resistant prostate cancer.
-
AACR 2026 data in animal models: complete responses at very low doses (0.1–0.3 mg/kg).
-
Preclinical; out-licensing targeted.
-
Sources: BioSpectator (Mar-2026); AlphaDistill.
-
-
AM201 (TNFα × IL-6) — autoimmune disease, including rheumatoid arthritis. Preclinical.
In vivo CAR-T
InCAR-T / StAb19 (CD19): - Uses the same CD19 binder sequence as nespecel, delivered as mRNA in a T-cell-targeted (CD3-directed "pTag") LNP from Strike Pharma (Sweden).
-
Selected for a Eurostars grant of up to EUR 1M in Feb-2026.
-
A parallel programme with GC Biopharma combines GC's mRNA-LNP platform and GMP capacity with AbClon's CAR and antibody know-how (Jun-2026).
-
Stage: discovery.
-
Sources: CB Insights/BioSpectator (Feb-2026); BioSpectator (Jun-2026).
NeuroTaG BBB shuttle
-
Shuttle antibodies against TfR1, IGF1R and CD98 for delivering drugs to the brain.
-
Discovery stage (IR, Mar-2026).
Non-pharmaceutical products and services
-
Research and diagnostic reagents, antibody detection reagents, and analytical reference standards such as pesticide-residue standards.
-
Sold mainly through public tenders to KDCA and MFDS/NIFDS.
-
Supplied via outsourced production (DART supply-contract filings).
-
AlphaDistill estimates about KRW 0.25bn of stable quarterly goods revenue.
Financial Narrative
Basis. K-IFRS standalone statements (AbClon has no subsidiaries). FY2021–FY2024 income-statement figures are rounded DART-derived values from Butler.works. FY2025 and balance-sheet data come from Valueline's DART-derived statements. All figures are in KRW bn.
Income statement
Revenue CAGR FY2021–FY2025: about 11.9% a year (from KRW 3.0bn to KRW 4.71bn; computed).
Notes
-
FY2025 detail is from Valueline (DART-derived).
-
The FY2025 EPS of KRW -933 is Valueline's figure.
-
No dividend has ever been paid. The company has an accumulated deficit of KRW 90.8bn at end-2025 (Valueline balance sheet), which legally rules out dividends.
Commentary.
Revenue: The top line is immaterial to valuation and lumpy. It follows the timing of government tenders more than any operating trend.
-
FY2024 fell to KRW 2.34bn because goods sales had to be booked on a net basis.
-
FY2025 doubled to KRW 4.71bn, about 87% of it booked in 1Q–3Q.
-
1Q26 was only KRW 0.43bn, far below the KRW 1.3–1.5bn that independent research had expected (AlphaDistill).
Losses: Operating losses widened every year from FY2022 (KRW -8.7bn) to FY2025 (KRW -17.6bn). The drivers were Phase 2 CAR-T clinical costs and manufacturing.
-
1Q26 showed a sharp cut: the operating loss fell 47% year on year, entirely because SG&A dropped from KRW 5.87bn to KRW 3.31bn.
-
2Q26 then saw losses jump back to KRW 6.2bn as Phase 2 dosing completed. The 1H26 operating loss (KRW 9.3bn) is essentially flat against 1H25 (KRW 9.1bn).
Gross margin: The FY2025 gross margin (24%) is low because personnel and depreciation are allocated into cost of sales.
Balance sheet
FY2021 balance-sheet data were not available in the sources reviewed.
Notes
-
Source: Valueline (DART-derived standalone).
-
Short-term debt consists of KRW 7.0bn of bank borrowings in every year plus short-term bonds/CB: KRW 5.52bn (FY2023) and KRW 10.10bn (FY2024).
-
Net debt is computed as total debt minus cash minus short-term financial instruments.
-
Shares outstanding come from Valueline's share-count series.
Commentary.
Funding pattern: Equity has been restored repeatedly through external capital. Equity more than doubled from KRW 29.4bn to KRW 60.4bn in FY2025 despite a KRW 17.9bn loss, because the company raised:
-
KRW 12.2bn from Chong Kun Dang (common equity).
-
KRW 25.2bn of perpetual CB, classified as equity.
-
KRW 10.8bn of CPS.
-
Gross external investment in 2025 was KRW 48.4bn (Korea Economic Daily, Dec-2025).
Pre-tax loss test: The KOSDAQ rule on pre-tax losses exceeding 50% of equity (법차손) had reached 55.4% at end-2024 (Dealsite). The 2025 equity raises were explicitly designed to cure it.
Property reclassification: In FY2025 about KRW 15bn of land moved from property, plant and equipment to investment property. PP&E land fell from KRW 19.08bn to KRW 4.07bn, and investment property of KRW 15.0bn appeared.
Cash flow
Notes
-
Source: Valueline trailing-twelve-month cash-flow series; the Dec-2025 column equals FY2025. FCF is computed as operating cash flow minus capex.
-
FY2025 financing breakdown:
-
Inflows of KRW 48.11bn: bonds KRW 25.15bn, CPS KRW 10.78bn, other equity KRW 12.17bn.
-
Repayment of KRW 10.1bn of short-term bonds.
-
-
Trailing twelve months to Jun-2026: operating cash flow KRW -13.64bn, capex KRW 0.20bn, FCF about KRW -13.8bn.
-
Quarterly cash burn in 1Q26 was estimated by independent research at about KRW 2.5–2.8bn (AlphaDistill). That looks optimistic given the 2Q26 loss.
Ratios
Ratios not meaningful or not disclosed
-
ROIC: not meaningful (negative NOPAT).
-
Net debt/EBITDA: not meaningful (net cash and negative EBITDA).
-
Cash conversion cycle: not disclosed and not meaningful at this scale.
-
All ratios are computed from the tables above.
Trend summary. AbClon has never made a profit. Its solvency depends on the equity market's willingness to fund it. The crisis point was FY2023–FY2024:
-
Current ratio near 1.1–1.3.
-
Short-term CB maturities.
-
An administrative-issue designation.
The 2025 raises reset the balance sheet. At about KRW 36bn of cash and short-term instruments (Jun-2026) and an underlying burn of about KRW 14–18bn a year, the company has roughly two years of runway, before:
-
Any AT101 launch costs borne by AbClon.
-
Any repayment if the perpetual CB call/step-up (coupon rising to 4% in year 4) prompts refinancing in 2028–29.
The main non-dilutive inflows in view are:
-
TCT milestones.
-
Henlius sales milestones, which would arrive only after a 2028 launch.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansFinancial Detail
Segment / revenue line (KRW Bn)
| Segment / revenue line (KRW Bn) | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Total revenue (single segment, KRW Bn) | 3.0 | 3.4 | 2.9 | 2.34 | 4.71 |
Operating income (single segment, KRW Bn) | -10.2 | -8.7 | -11.6 | -15.6 | -17.63 |
Operating margin (%) | -340 | -256 | -400 | -667 | -374 |
Revenue YoY growth (%) | — | 13.3 | -14.7 | -19.3 | 101.3 |
Revenue type, 2Q26 (% of quarterly revenue)
| Revenue type, 2Q26 (% of quarterly revenue) | Share |
|---|---|
Goods (reagents, standards, antibody detection reagents) | 85% |
Services | 15% |
Income Statement and Per-Share Data
| Metric (KRW Bn unless stated) | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Revenue (KRW Bn) | 3.0 | 3.4 | 2.9 | 2.34 | 4.71 |
Cost of sales (KRW Bn) | — | — | — | — | 3.57 |
Gross profit (KRW Bn) | — | — | — | — | 1.14 |
SG&A incl. R&D (KRW Bn) | — | — | — | — | 18.77 |
R&D expense within SG&A (KRW Bn) | — | — | — | — | 14.43 |
Operating income (KRW Bn) | -10.2 | -8.7 | -11.6 | -15.6 | -17.63 |
EBITDA (KRW Bn) | — | — | — | — | -16.80 |
Pre-tax income (KRW Bn) | — | — | — | — | -17.90 |
Net income (KRW Bn) | -10.2 | -9.3 | -12.9 | -16.3 | -17.90 |
EPS basic (KRW) | — | — | — | — | -933 |
Dividends per share (KRW) | 0 | 0 | 0 | 0 | 0 |
Gross margin (%) | — | — | — | — | 24.2 |
Operating margin (%) | -340 | -256 | -400 | -667 | -374 |
EBITDA margin (%) | — | — | — | — | -357 |
Net margin (%) | -340 | -274 | -445 | -697 | -380 |
Financial Analysis
| Item | Value (KRW Bn) |
|---|---|
Revenue | 5.30 |
Gross profit | 0.67 |
R&D | 14.07 |
Operating income | -17.85 |
Net income | -17.42 |
Total assets | 64.50 |
Cash | 30.37 |
Short-term financial instruments | 6.00 |
Total debt | 7.00 |
Total liabilities | 11.43 |
Equity | 53.07 |
Net cash | 29.37 |
Cash plus short-term instruments | 36.3 (NewDaily cites KRW 36.3bn) |
Revenue History
| Quarter | Revenue (KRW Bn) | Operating loss (KRW Bn) | Net loss (KRW Bn) | EPS (KRW) | Source |
|---|---|---|---|---|---|
1Q26 | 0.43 | 3.06 | 2.78 | -145 | DART via AlphaDistill |
2Q26 | 1.6 | 6.2 | 6.0 | — | Valueline, 20 Aug 2026 |
1H26 | 2.1 | 9.3 | 8.8 | — | NewDaily, Sep-2026 |
Balance Sheet and Share Count (millions)
| Metric (KRW Bn) | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Total assets (KRW Bn) | — | 54.02 | 45.43 | 48.18 | 70.74 |
Cash and cash equivalents (KRW Bn) | — | 5.29 | 12.25 | 18.86 | 39.01 |
Short-term financial instruments (KRW Bn) | — | 18.84 | 6.57 | 3.00 | 6.00 |
Short-term debt incl. current CB (KRW Bn) | — | 7.00 | 12.52 | 17.10 | 7.00 |
Long-term debt incl. non-current CB (KRW Bn) | — | 4.56 | 0 | 0 | 0 |
Total debt (KRW Bn) | — | 11.56 | 12.52 | 17.10 | 7.00 |
Net debt (KRW Bn, negative = net cash) | — | -12.57 | -6.30 | -4.76 | -38.01 |
Total liabilities (KRW Bn) | — | 17.28 | 18.20 | 18.77 | 10.30 |
Total equity (KRW Bn) | — | 36.73 | 27.22 | 29.40 | 60.43 |
Goodwill and intangibles (KRW Bn) | — | 0.42 | 0.53 | 0.50 | 0.49 |
Working capital (KRW Bn) | — | 16.37 | 1.72 | 5.12 | 36.68 |
Accumulated deficit (KRW Bn) | — | -43.67 | -56.58 | -72.88 | -90.79 |
Shares outstanding (millions) | 15.28 | 15.32 | 15.53 | 17.43 | 19.73 |
Cash Flow
| Metric (KRW Bn) | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Operating cash flow (KRW Bn) | — | — | — | — | -13.82 |
Capex incl. intangibles (KRW Bn) | — | — | — | — | 0.61 |
Free cash flow (KRW Bn) | — | — | — | — | -14.43 |
Financing cash flow (KRW Bn) | — | — | — | — | 37.73 |
Dividends paid (KRW Bn) | 0 | 0 | 0 | 0 | 0 |
Share buybacks (KRW Bn) | 0 | 0 | 0 | 0 | 0 |
Returns & Leverage Ratios (%) and Financial Ratios (x)
| Ratio | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|
ROE on ending equity (%) | -25.3 | -47.4 | -55.4 | -29.6 |
ROA on ending assets (%) | -17.2 | -28.4 | -33.8 | -25.3 |
Current ratio (x) | 2.91 | 1.10 | 1.28 | 4.92 |
Debt to equity (x) | 0.31 | 0.46 | 0.58 | 0.12 |
Asset turnover (x) | 0.06 | 0.06 | 0.05 | 0.07 |
Interest coverage, operating income / interest expense (x) | — | — | — | -41.0 |
Revenue by Region
| Region (KRW Bn) | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
Total revenue, all regions (KRW Bn) | 2.9 | 2.34 | 4.71 |
Share Price and Market Valuation
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Year-end share price (KRW) | — | 12,800 | 14,820 | 14,120 | 42,500 |
Year-end market cap (KRW Bn) | — | 196.07 | 230.16 | 246.04 | 812.27 |
Year-end shares outstanding (millions) | 15.28 | 15.32 | 15.53 | 17.43 | 19.73 |
Price-to-book at year-end (x) | — | — | 8.45 | 8.37 | 13.44 |
Share Price History
| Date | Price (KRW) | Source |
|---|---|---|
11-Feb | 65,100 | Dailypharm |
| — | 95,800 | StockHub; Investing.com |
31-Mar | 56,700 | Valueline |
18-May | 39,250 | AlphaDistill |
30-Jun | 27,800 | Valueline |
9-Jul | 22,650 | AlphaDistill |
4-Aug | 26,500 | AlphaDistill |
26-Aug | 28,450 | Valueline |
29-Sep | 21,750 | Valueline |
15-Oct (12:15) | 21,350 | Valueline |
Valuation Multiples
| Multiple | AbClon | Notes |
|---|---|---|
P/E | Not meaningful (losses) | Valueline shows about -26.8x |
EV/Sales (trailing twelve months) | About 75x | EV ≈ KRW 426bn market cap minus KRW 29.4bn net cash ≈ KRW 397bn; TTM revenue KRW 5.30bn. Computed. |
P/B | About 8.8x | Valueline |
Peer: Curocell market cap | About KRW 412bn (Jul-2026) | AlphaDistill |
Capital Instruments
| Instrument | Amount | Terms |
|---|---|---|
Short-term bank borrowings | KRW 7.0bn | Rolled since at least FY2022 |
Series 2 CB | Converted or partly outstanding; KRW 20bn originally announced, from a KRW 19bn package paid in | Maturity 29-Nov-2029; conversion price KRW 16,244. |
Series 3 perpetual CB | KRW 25.2bn | Equity-classified; 30-year maturity (28-Oct-2055); issuer call after 4 years; coupon steps up to 4% in year 4 and +1% a year after, which effectively encourages calling or converting by about Oct-2029 |
CPS (multiple series) | — | Non-redeemable; equity |
Analyst Conclusions
Management guidance (as of Oct-2026)
-
Final nespecel Phase 2 data and an MFDS expedited approval filing by end-2026, targeting launch in 2027 via Chong Kun Dang.
-
HLX22 Phase 3 topline in 1H27 per AbClon, or 2H27 per Henlius' latest guidance; 2028 global launch.
-
AT501 IND in 2026.
-
In vivo CAR-T partnering.
-
Türkiye IND in 2026.
-
No financial guidance.
-
Sources: Dealsite; NewDaily; AbClon IR.
Consensus growth expectations
None available. Independent research estimates FY2026 standalone revenue of about KRW 4.3bn with an operating loss of about KRW 13bn. This is not consensus, and 1H26 actuals (operating loss KRW 9.3bn) suggest the loss estimate is optimistic (AlphaDistill; NewDaily).
Bull case
-
Nespecel approval in 2027 with a differentiated label. If final Phase 2 data hold a CR rate near the 63–68% interim, nespecel would match Limkato (CR 67.1%) and beat the imported products. Expedited, orphan and GIFT designations, together with CKD's distribution, could support uptake. A post-CAR-T relapse label would be unique.
-
HLX22 success makes AbClon a royalty company. A positive PHAROS001 readout, building on the Phase 2 PFS hazard ratio of 0.20, would unlock sales milestones (USD 30M gross) and royalties of 3–5% (roughly 65% net to AbClon after Alligator). It would also add value through HLX49 and other derivatives.
-
Platform licensing. The in vivo CAR-T market has absorbed large acquisitions. An in vivo CD19 programme using a clinically validated binder (Strike, GC) or a licence for AM109 or zCAR-T could bring meaningful non-dilutive cash and re-rate the platform.
Bear case
-
Second to market in a small, price-controlled country. Curocell's market cap halved after approval as reimbursement and launch timing dragged. Nespecel enters behind it with a smaller partner network and no ex-Korea data, and in vivo CAR-T may shorten the life of the ex vivo category.
-
HLX22 economics are thin and late. Topline has slipped to 2H27 and launch would come no earlier than 2028. Milestones depend on sales, and zanidatamab may become the HER2 backbone first. A positive trial might still deliver modest cash to AbClon before about 2030.
-
Dilution is the base case. Burn is about KRW 14–18bn a year against about KRW 36bn of liquidity. Convertibles at KRW 16,244–18,223 are near the money, with a lock-up expiring 28-Oct-2026. The perpetual CB step-up in 2029 adds refinancing pressure, while the stock trades at about 8.8x book and about 75x EV/Sales.
Catalysts and monitorables (next 12 months)
| Expected timing | Catalyst / monitorable |
|---|---|
| 28-Oct-2026 | Lock-up expiry on the Series 3 CB and CPS |
| By 14-Nov-2026 | 3Q26 report: cash burn trajectory |
| 4Q26 | Final nespecel Phase 2 data, any ASH 2026 presentation, and the MFDS approval filing |
| 4Q26–1H27 | Türkiye IND and TCT milestones; AT501 IND; Asan post-CAR-T investigator-trial IND |
| 2026–2027 | In vivo CAR-T licence or co-development deal (unconfirmed discussions) |
| 2,026 | HLX49 IND by Henlius |
| 1H27 vs 2H27 | Henlius' progress updates on PHAROS001 enrolment (428/550 in Aug-2026) and topline timing |
| Ongoing | Limkato reimbursement and uptake as a read-across for nespecel pricing |
| Ongoing | Any new equity-linked financing |
Analyst verdict
AbClon is a high-quality discovery engine that has struggled to turn science into cash. Its NEST platform has produced two assets that would be a creditable track record for a much larger company.
The first is AC101/HLX22. It is now in a roughly 550-patient global Phase 3, fully funded by Henlius, after a Phase 2 with a PFS hazard ratio of 0.20. The second is nespecel. It is the only late-stage CD19 CAR-T with a proprietary, non-FMC63 binder, and its interim CR rate of 63–68% is competitive with every approved CD19 product.
The financial picture is far weaker:
-
Revenue is a byproduct of reagent tenders (KRW 4.7bn in FY2025).
-
Operating losses have widened to about KRW 18bn.
-
The balance sheet has been repeatedly rebuilt through convertibles priced below today's share price.
-
The economics of the lead antibody were largely given away in 2016–2018. AbClon received USD 11M upfront and is left with sales-based milestones and 3–5% royalties, of which it keeps only about 65%.
The equity story therefore rests on nespecel's commercial and licensing value and on platform optionality, especially in vivo CAR-T. Both face clear headwinds. Curocell's Limkato won the Korean race in April 2026, and its post-approval share price fall shows how cautiously the market values a domestic CAR-T launch.
At about KRW 0.43–0.47tn, the market is pricing substantial success. That is roughly 8.8x book with about two years of cash, and it comes after the stock has fallen sharply from its February 2026 peak.
Our assessment is "high-risk, event-driven — neutral until final nespecel data."
What would change our view:
Positive: final Phase 2 data that hold CR above 60% across the full cohort, together with an ex-Korea licence for nespecel or the in vivo platform.
Negative: further slippage in HLX22 timing, or a financing before the nespecel filing.
Sizing should reflect binary clinical, regulatory and dilution risk over the next 12 months.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansExecutive Leadership
Executive Leadership Team
| Name | Title | Background | Source |
|---|---|---|---|
Lee Jong-seo (이종서) | Founder, CEO and Representative Director; largest shareholder | Chong Kun Dang R&D researcher 1991–1995. Worked with the Royal Swedish Academy / KTH on the Human Protein Atlas from 2003. Co-founded AbClon with Prof. Mathias Uhlén in 2010. | SmartToday; BioSpectator |
Prof. Mathias Uhlén | Co-founder | Leads the Human Protein Atlas (KTH, Sweden). | BioSpectator |
Lee Yong-jun (이용준) | Head, CAR-T Center | At Chong Kun Dang 2013–2020 | Dealsite (May-2025) |
Lee Yoon (이윤) | Head, Clinical Research Institute | Spokesperson for the nespecel regulatory strategy | eToday; BioSpectator (Jul-2025) |
Hwang Jin-ha (황진하) | Director, Head of Business Development | Leads partnering at BIO USA 2026 | Dealsite (Jul-2026) |
Kim Kyu-tae (김규태) | CFO, as of 2019 | — | BioSpectator (2019) |
Major Shareholders
| Holder | Shares | Stake | Basis / date | Source |
|---|---|---|---|---|
Lee Jong-seo (CEO) | 1,401,675 | ~7.0–7.3% | Q3-2025 report; 7.66% before the CKD placement, 7.34% after | Dailypharm; Dealsite |
Lee Jong-seo plus related parties (including his son) | — | 13.06–15.07% (sources differ) | May-2025 | Dailypharm; SmartToday |
Chong Kun Dang Co., Ltd. | 1,400,000 | ~7.1–7.3%; about 7.0% on the 19.95M share base | Placement at KRW 8,723 per share, paid 19-May-2025. | Dealsite; Dailypharm; AlphaDistill |
Daily Partners funds | CB conversion right over 1,231,223 shares (Series 2 CB, KRW 20bn announced) plus CPS | — | Oct-2024 terms; KRW 19bn of the package paid in Dec-2024 | BioSpectator; Finance Scope |
VC holders of the perpetual CB and CPS (DSC Investment, Paratus Investment, Dongyu Investment, AlphaView Partners, Winvest Venture Investment) | Conversion price KRW 18,223 | — | Lock-up expires 28-Oct-2026 | Dealsite; AlphaDistill |
Foreign ownership | — | 11.52% | Jun-2021 (historical) | Kyobo Securities |
Competitive Landscape
Key Competitors
| Competitor | Product | Status / data | Positioning vs nespecel |
|---|---|---|---|
Novartis | Kymriah (tisagenlecleucel) | Approved; first CAR-T in Korea. Pivotal JULIET: ORR 50%, CR 32%. | Incumbent in Korea. AbClon argues it has a higher CR rate and a different epitope. |
Gilead / Kite | Yescarta (axi-cel); Tecartus | Approved globally. ZUMA-1: ORR 72%, CR 51%. | Global leader; FMC63/CD28 construct |
Bristol Myers Squibb | Breyanzi (liso-cel) | Approved globally. TRANSCEND: ORR 73%, CR 54%. | Strong safety profile |
Autolus | Aucatzyl (obe-cel; modified FMC63) | Approved in the US for adult ALL | Fast-off-rate binder is a conceptually similar argument |
Curocell (Korea) | Limkato (anbal-cel) | MFDS approved 29-Apr-2026. Phase 2: ORR 75.3%, CR 67.1%. Reimbursed launch targeted around Sep-2026. | Closest domestic rival and now first to market. Market cap about KRW 412bn (Jul-2026). |
AstraZeneca (EsoBiotec), AbbVie (Capstan), Gilead (Interius), BMS (Orbital) | In vivo CAR-T | Clinical or preclinical | Long-term disruptors of ex vivo CAR-T, including AbClon's own |
Korean next-generation CAR-T developers (e.g., Verismo) | SynKIR-110 and others | Early clinical | Future domestic competition |
Roche | Herceptin (trastuzumab) plus chemotherapy | Standard of care | HLX22 is added to it, not substituted |
Merck & Co. | Keytruda plus trastuzumab plus chemotherapy (PD-L1 CPS ≥1) | Approved | Allowed in both arms of PHAROS001 |
Jazz / Zymeworks / BeOne | Ziihera (zanidatamab), a biparatopic HER2 antibody | HERIZON-GEA-01 positive (n=914). Zanidatamab plus tislelizumab plus chemotherapy reached median OS of 26.4 months. Second interim showed a significant OS gain for zanidatamab plus chemotherapy. sBLA planned for 1H26. | The most direct competitor in dual-epitope HER2 blockade. It may replace trastuzumab as the backbone before HLX22 reads out, which complicates PHAROS001's comparator relevance. |
AstraZeneca / Daiichi Sankyo | Enhertu (T-DXd) | Approved later-line in gastric cancer; also a combination partner | Henlius is turning a competitor into a combination partner |
Roche | Perjeta (pertuzumab) | Failed to win approval in gastric cancer (JACOB) | Shows dual HER2 blockade is not guaranteed to work |
Peer Comparison FY2025
| Metric | AbClon | Curocell | Henlius (partner, for scale) | Zymeworks (HER2 competitor) |
|---|---|---|---|---|
Revenue | KRW 4.7bn (FY2025) | Not compiled | Not compiled (66 approvals globally) | Not compiled |
Revenue growth | +101% (FY2025) | Not compiled | Not compiled | Not compiled |
Operating margin | -374% (FY2025) | Not compiled | Not compiled | Not compiled |
R&D intensity | 306% of revenue (FY2025) | Not compiled | Not compiled | Not compiled |
Market cap | ~KRW 426–467bn (Oct-2026) | ~KRW 412bn (Jul-2026) | Not compiled | Not compiled |
Lead asset stage | CAR-T: MFDS filing by 2026; HER2 antibody (partnered) in Phase 3 | CAR-T approved in Korea (Apr-2026) | Commercial | HER2 bispecific approved (biliary tract); first-line GEA filing |



